Sugi Predict

Sugi Predict / Compounds / SCHEMBL13253331

SCHEMBL13253331

SCHEMBL13253331

Nc1ccc(C(=O)CC2(O)C(=O)Nc3c(Cl)ccc(Cl)c32)cc1

nearest known ligand 0.73

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ FLI1 Q01543 6/20 0.73
▸ EWSR1 Q01844 6/20 0.73
▸ ERG P11308 1/20 0.73
▸ ETV1 P50549 1/20 0.73
▸ ALDH1A1 P00352 3/20 0.65
▸ KMT2A Q03164 2/20 0.65
▸ MEN1 O00255 1/20 0.65
▸ HTT P42858 1/20 0.65
▸ NPSR1 Q6W5P4 1/20 0.65
▸ MMP8 P22894 10/20 0.48
▸ MMP9 P14780 8/20 0.48
▸ MMP2 P08253 8/20 0.48
▸ TP53 P04637 1/20 0.46
▸ MAPT P10636 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29810788 0.90 FLI1 (0.73) FLI1EWSR1ERGETV1ALDH1A1
SCHEMBL17669239 0.90 FLI1 (0.73) FLI1EWSR1ERGETV1ALDH1A1
SCHEMBL17679856 0.90 FLI1 (0.73) FLI1EWSR1ERGETV1ALDH1A1
SCHEMBL13253318 0.89 FLI1 (0.77) FLI1EWSR1ERGETV1ALDH1A1
SCHEMBL29810795 0.88 FLI1 (0.72) FLI1EWSR1ERGETV1ALDH1A1
SCHEMBL17679834 0.88 FLI1 (0.72) FLI1EWSR1ERGETV1ALDH1A1
SCHEMBL17679830 0.88 FLI1 (0.72) FLI1EWSR1ERGETV1ALDH1A1
SCHEMBL17669241 0.88 FLI1 (0.72) FLI1EWSR1ERGETV1ALDH1A1
SCHEMBL13253333 0.88 FLI1 (0.75) FLI1EWSR1ERGETV1ALDH1A1
SCHEMBL17679858 0.88 FLI1 (0.75) FLI1EWSR1ERGETV1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3795563-B1 INDOLINE ANALOGS AND USES THEREOF ONCTERNAL THERAPEUTICS INC (US) 2024-07-17 — — EP disclosed
EP-3204376-B1 INDOLINONE COMPOUNDS AND USES THEREOF ONCTERNAL THERAPEUTICS INC (US) 2023-04-19 — — EP disclosed
EP-3795563-A1 INDOLINE ANALOGS AND USES THEREOF Oncternal Therapeutics, Inc. (US) 2021-03-24 — — EP disclosed
US-10711008-B2 Indoline analogs and uses thereof Oncternal Therapeutics, Inc. (US) 2020-07-14 — — US disclosed
EP-3436434-B1 INDOLINE ANALOGS AND USES THEREOF ONCTERNAL THERAPEUTICS INC (US) 2020-07-08 — — EP disclosed
US-20190337951-A1 INDOLINE ANALOGS AND USES THEREOF GEORGETOWN UNIVERSITY 2019-11-07 — — US disclosed
US-10351569-B2 Indoline analogs and uses thereof Oncternal Therapeutics, Inc. (US) 2019-07-16 — — US disclosed
US-9987251-B2 Indolinone compounds and uses thereof Oncternal Therapeutics, Inc. (US) 2018-06-05 — — US disclosed
US-9987251-B2 Indolinone compounds and uses thereof Oncternal Therapeutics, Inc. (US) 2018-06-05 — — US disclosed
US-9895352-B2 Indolinone compounds and uses thereof Oncternal Therapeutics, Inc. (US) 2018-02-20 — — US disclosed
US-9045415-B2 Targeting of EWS-FLI1 as anti-tumor therapy GEORGETOWN UNIVERSITY (US) 2015-06-02 — — US disclosed
US-9045415-B2 Targeting of EWS-FLI1 as anti-tumor therapy GEORGETOWN UNIVERSITY (US) 2015-06-02 — — US disclosed
US-20150051260-A1 METHODS AND COMPOSITIONS FOR TREATING EWINGS SARCOMA FAMILY OF TUMORS GEORGETOWN UNIVERSITY (US) 2015-02-19 — — US disclosed
US-20150051260-A1 METHODS AND COMPOSITIONS FOR TREATING EWINGS SARCOMA FAMILY OF TUMORS GEORGETOWN UNIVERSITY (US) 2015-02-19 — — US disclosed
WO-2013155341-A1 METHODS AND COMPOSITIONS FOR TREATING EWINGS SARCOMA FAMILY OF TUMORS GEORGETOWN UNIVERSITY (US) 2013-10-17 — — WO disclosed
US-20100167994-A1 TARGETING OF EWS-FLI1 AS ANTI-TUMOR THERAPY GEORGETOWN UNIVERSITY (US) 2010-07-01 — — US disclosed
US-20100167994-A1 TARGETING OF EWS-FLI1 AS ANTI-TUMOR THERAPY GEORGETOWN UNIVERSITY (US) 2010-07-01 — — US disclosed
US-20100004179-A1 TARGETING OF EWS-FLI1 AS ANTI-TUMOR THERAPY GEORGETOWN UNIVERSITY 2010-01-07 — — US disclosed
US-20100004179-A1 TARGETING OF EWS-FLI1 AS ANTI-TUMOR THERAPY GEORGETOWN UNIVERSITY 2010-01-07 — — US disclosed
WO-2008083326-A2 TARGETING OF EWS-FLI1 AS ANTI-TUMOR THERAPY GEORGETOWN UNIVERSITY (US) 2008-07-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100004179-A1 TARGETING OF EWS-FLI1 AS ANTI-TUMOR THERAPY EWSR1, FLI1, PELI1 FLI1 2/4885EWSR1 1/4885ERG 47/4885
US-20190337951-A1 INDOLINE ANALOGS AND USES THEREOF FLI1, EWSR1, IKZF1 FLI1 1/4885EWSR1 2/4885ERG 5/4885
US-20150051260-A1 METHODS AND COMPOSITIONS FOR TREATING EWINGS SARCOMA FAMILY OF TUMORS EWSR1, FLI1, CDC73 FLI1 2/4885EWSR1 1/4885ERG 81/4885
US-10711008-B2 Indoline analogs and uses thereof FLI1, EWSR1, IKZF1 FLI1 1/4885EWSR1 2/4885ERG 5/4885
US-10351569-B2 Indoline analogs and uses thereof FLI1, EWSR1, IKZF1 FLI1 1/4885EWSR1 2/4885ERG 5/4885
US-20100167994-A1 TARGETING OF EWS-FLI1 AS ANTI-TUMOR THERAPY EWSR1, FLI1, PELI1 FLI1 2/4885EWSR1 1/4885ERG 47/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.